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Poster Session I 39alone: 3, other combination chemotherapy: 9 and 1 underwent re-
duced intensity allogeneic transplantation. Two pts were not fit to
receive further treatment and had rapidly progressive disease
(PD). Of the treated pts, 6 achieved CR (4 subsequently pro-
gressed), 5 PR and 7 had PD. Eleven pts remain alive (only 2 in
CR) with PD accounting for all deaths. With a median follow-up
of 31 months (m) post relapse for living pts, median PFS from the
time of relapse post-ASCT was 5 m and OS was 34 m. No signifi-
cant predictors of PFS could be identified. For OS, univariate anal-
ysis identified time to relapse (TTR; p5 0.011), performance status
(PS; p5 0.010) and total IPI score (p5 0.041) as being statistically
significant. Only TTR remained significant on the multivariate
model. TTR less than 12 months portends a very poor outcome
(2 year OS 0% compared to 62% form TTR .12 m; p\ 0.001).
Conclusion: Pts with MCL who relapse after ASCT do poorly, es-
pecially those relapsing within one year of ASCT. New therapeutic
approaches incorporating maintenance therapy post-ASCT or the
use of novel agents such as bortezomib or mTOR inhibitors should
be explored in this group.100
FLUID RELATED COMPLICATIONS WITH FILGRASTIM (G-CSF) 10 MCG/
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Background:High dosemelphalan followed by peripheral blood
stem cell (PBSC) transplantation is an established therapy for AL
amyloidosis. One limitation is the frequent fluid related complica-
tions that occur during PBSC mobilization (Blood 2004:1143a).
The development of fluid related complications during mobiliza-
tion predicts decreased survival after PBSC transplant (Blood
2005;106:3353). At Mayo Clinic, G-CSF 10 mcg/kg once daily
was the standard until 2004. In attempt to reduce fluid related com-
plications the practice changed to G-CSF 5 mcg/kg twice daily in
July 2004. It is unknown if this change impacted the incidence of
fluid related complications during PBSC mobilization. Methods:
We conducted a retrospective evaluation of patients with amyloid-
osis undergoing PBSCmobilization at Mayo Clinic. Following IRB
approval, patients were identified by reviewing theMayoClinic dys-
proteinemia data base and data extracted from the medical record.
Forty-six patients from the once daily and 22 patients from the twice
daily were excluded due to use of mobilization agents in addition to
G-CSF, second mobilization, syngeneic transplant or consent re-
fusal. A fluid related complication was defined as new peripheralComparison of Complications based on G-CSF Schedule of
Administration
Once
daily
Filgrastim
n 5 123 N (%)
Twice
daily
Filgrastim
n 5 182 N (%) p value
Fluid Complications 63 (50) 93 (51) 0.9
Hospitalization 28 (23) 24 (13) 0.03
Hospitalization related
to fluid complication
21 (17) 10 (5) 0.001
Diuretic adjustment
needed
42 (34) 89 (49) 0.012
Non-pharmacological
intervention*
10 (8) 9 (5)
Death prior to PBSC
Transplant
2 (1.6) 4 (2.2)
Patient did not undergo
PBSC transplant
9 (7.3) 37 (20)
*Thoracentesis, Paracentesis, Hemodialysis, Pleurodesis, and Me-
chanical Ventilation.edema, pleural effusion or ascites, or initiation of supportive therapy
(diuretics, albumin, or dopamine) to promote diuresis. Results:
From 7/98 to 8/03, 123 patients received once daily G-CSF.
From 7/04 to 8/07, 182 patients received twice daily G-CSF. Organ
involvement was similar in both series; single organ (43% vs 36%; p
5 0.2), two organs (38% vs 62%; p 5 0.5) and 3 or more organs
(22% vs 26%; p5 0.5).Most patients had either kidney involvement
(65% vs 71%; p5 0.2) or heart involvement (51% vs 57%; p5 0.3).
Baseline edema (61% vs 53% (p 5 0.06)) and baseline diuretic use
(58% vs 55% (p 5 0.7)) was similar in both groups. Fluid related
complications occurred with similar frequency regardless of admin-
istration schedule, 50% vs 51% (p5 0.9). Two patients in the once
daily and 4 patients in the twice daily administration died prior to
PBSC transplant. In patients that received a PBSC transplant, sur-
vival was similar at day 100; 88% vs 92% and one year; 83% vs 88%
(p 5 0.6). Conclusion: Changing from once daily to twice daily
G-CSF administration in patients with amyloidosis did not impact
the incidence of fluid related complications or mortality at day 100
or one year after PBSC transplant.101
PHASE II TRIAL EVALUATING APREPITANT (AP) FOR PREVENTION OF
NAUSEA AND VOMITING SECONDARY TO HIGH-DOSE CYCLOPHOSPHA-
MIDE (CY) ADMINISTERED TO PATIENTS UNDERGOING AUTOLOGOUS
(A) PERIPHERAL BLOOD PROGENITOR CELL (PBPC) MOBILIZATION
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Background:Adequate PBPCmobilization in the range of 2–5
106 CD341 cells/kg body weight is a prerequisite for administration
of high-dose chemotherapy and A-PBPC transplant. Cy and filgras-
tim combination provides a better PBPC yield as compared to fil-
grastim, which has a failure rate of 15–20%. In this setting, high-
dose Cy is associated with significant nausea and vomiting. Ap is
a new antiemetic that is a Neurokinin-1 receptor antagonist and
may reduce the incidence of this side effect. We have conducted
a phase II trial evaluating efficacy and safety of adding Ap to stan-
dard antiemetic combination of 5-HT3 antagonists and adjusted
dose of corticosteroids. Primary objective of this study was the con-
trol of acute vomiting without the use of rescue medications at 24
hours post Cy. The data of the first interim report are presented.
Methods: From May 2005 to May 2007, 22 pts were enrolled,
four of whom are not evaluable for response. Three pts did not re-
ceive Ap; one withdrew consent after a single dose. All received Cy 4
gm/m2 and filgrastim (10–16 mcg/kg/d) for stem cell mobilization.
Granisetron 1 mg, dexamethasone 10 mg and Ap 125 mg was ad-
ministered orally 1 hour before Cy followed by Ap 80 mg once daily
 2 days. This study used Simon’s optimal two-stage design con-
strained to fewer than 40 pts with 10% type I error and 85% statis-
tical power. Ap is considered effective if it prevents nausea and
vomiting in at least 65% of patients. Ap is judged ineffective if the
rate of vomiting control was 45% or less. Results: Ten (55%) of
18 response-evaluable pts had no vomiting episodes and received
no rescue medications during the first 24 hours following Cy. Of
those who did not achieve the primary endpoint, four pts reported
no vomiting episodes but received rescue medications. The other
four pts had at least one vomiting episode and one received rescue
anti-emetic. Ten pts had no delayed vomiting (25–120 hrs). Ten
pts reported no nausea in 24 hours and five pts experienced mild
nausea. Only 6/18 (33%) pts experienced moderate to severe de-
layed nausea (25–120 hrs). No toxicities related to Ap were noted
for any patients. All pts had adequatemobilization of stem cells (me-
dian CD341: 7.57  106/kg) and proceeded to A-PBPC transplant.
Conclusion: The results of this interim analysis justify continua-
tion to stage 2 with enrollment of 17more patients. Ap has potential
to effectively control nausea and emesis in pts receiving high-dose
Cy.
